Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ERAS vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ERAS Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–2 Matrix Metrics)

ERAS Overall Winner 6-Pillar Tally: ERAS 3 – 2 CAPR (1 Tie) Matrix Metrics: ERAS 6 – 2 CAPR

As of Nov 16, 2026, Erasca, Inc. (ERAS) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ERAS carries a Unified Composite Score of 36.9/100 (SELL) at $14.95 (N/M Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although ERAS compares more favorably head-to-head, both ERAS (36.9/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ERAS is currently in a Breakdown options structure phase (RSI 51.6); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ERAS vs CAPR
ERAS NASDAQ Head-to-Head Winner
Erasca, Inc. Common Stock
Pharmaceutical Preparations
$14.95
-4.57% 1D
Market Cap $5.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.31β · 81% Vol
Unified Composite Score
36.9 / 100 SELL
Tech 15.0 Fund 47.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.6 · SMA20: $14.91 · SMA50: $14.94
CAPR NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (ERAS 3 – 2 CAPR)

Columns: Metric · ERAS · CAPR
1. Valuation Multiples CAPR
Forward P/E N/M 78.7x
Trailing P/E N/M 78.7x
PEG Ratio N/M 0.38x
EV / Revenue N/M 57.8x
2. Growth & Scale ERAS
Revenue Growth (YoY) +0.0% -7.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $11M
Market Cap $5.5B $595.4M
3. Profitability & Quality ERAS
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -48.7% -100.5%
4. Balance Sheet & Cash Flow ERAS
Cash Generation (TTM) -$252M -$146M
Cash Flow Margin N/A N/A
Net Cash / Leverage $2.2M Net Debt (0.12x D/E) $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 89.2% (13th %ile) 637.1% (89th %ile)
Put/Call OI Skew N/A 1.57x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ERAS (6) vs CAPR (2)
Institutional Metric ERAS CAPR Criterion Row Edge
Market Capitalization
Scale
$5.5B $595.4M Larger Scale ERAS
Trailing P/E Ratio
Valuation
N/M 78.7x Lower Multiple CAPR
Forward P/E Ratio
Valuation
N/M 78.7x Lower Multiple CAPR
Revenue Growth (YoY)
Growth
+0.0% -7.9% Higher Growth ERAS
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-48.7% -100.5% Higher ROE ERAS
52-Week Range Position
Momentum
57% ($2–$24) 15% ($3–$40) Stronger Trend ERAS
Beta / 30D Volatility
Risk Regime
2.31β · 81% Vol 1.52β · 152% Vol Lower Realized Risk ERAS
Unified Institutional Score
Composite Signal
36.9 / 100 (SELL) 28.0 / 100 (SELL) Higher Composite ERAS
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$252M ($2.2M Net Debt (0.12x D/E)) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +14.62 pp
ERAS: +11.61% · CAPR: +26.23%
3M Horizon CAPR +37.06 pp
ERAS: -17.43% · CAPR: +19.63%
6M Horizon ERAS +116.67 pp
ERAS: +46.09% · CAPR: -70.58%
1Y Horizon ERAS +441.6 pp
ERAS: +488.39% · CAPR: +46.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ERAS vs CAPR. Trailing 12-month operating profitability (ERAS 0.0% vs CAPR 0.0%) and valuation multiples (ERAS N/M vs CAPR 78.7x Forward P/E) are benchmarked directly in Pillar 4 below.

ERAS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-48.7% · N/M
CAPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-100.5% · 78.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ERAS BREAKDOWN
87d in phase · OBV NEUTRAL
Current IV 89.2%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ERAS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ERAS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ERAS vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Erasca, Inc. (ERAS) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ERAS carries a Unified Composite Score of 36.9/100 (SELL) at $14.95 (N/M Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although ERAS compares more favorably head-to-head, both ERAS (36.9/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ERAS is currently in a Breakdown options structure phase (RSI 51.6); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ERAS leads the Growth & Scale pillar: ERAS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ERAS generates N/A in USD-normalized revenue versus $11M for CAPR. In operating R&D and SG&A reinvestment, ERAS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

CAPR screens cheaper on headline valuation multiples. ERAS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ERAS (-48.7% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ERAS carries 89.2% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.31β · 81% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.